OBJECTIVES: To analyze the expression and potential role of interleukin (IL) 21 in the pathogenesis of Vogt-Koyanagi-Harada (VKH) disease. METHODS: Blood samples were obtained from patients with VKH disease and from healthy control subjects. Serum IL-21 level and IL-21 messenger RNA (mRNA) expression by peripheral blood mononuclear cells (PBMCs) were determined by enzyme-linked immunosorbent assay and by reverse transcriptase-polymerase chain reaction, respectively. Interleukin 17 and interferon γ levels in the supernatants of PBMCs and CD4(+) T cells cultured with anti-CD3 and anti-CD28 antibodies in the presence or absence of recombinant IL-21 were detected by enzyme-linked immunosorbent assay. RESULTS: The results showed a significantly increased serum IL-21 level, as well as higher IL-21 mRNA expression by PBMCs, in patients having chronic or recurrent active VKH disease compared with patients having inactive VKH disease and with controls. In vitro experiments showed that recombinant IL-21 significantly increased IL-17 production by PBMCs and by CD4(+) T cells from patients and from controls. However, recombinant IL-21 did not affect interferon γ expression by PBMCs or by CD4(+) T cells. CONCLUSION: Interleukin 21 may be involved in the pathogenesis of chronic or recurrent VKH disease, possibly by promoting IL-17 secretion. CLINICAL RELEVANCE: Findings from the present study suggest that IL-21 may be a potential target in the development of therapy for VKH disease.
OBJECTIVES: To analyze the expression and potential role of interleukin (IL) 21 in the pathogenesis of Vogt-Koyanagi-Harada (VKH) disease. METHODS: Blood samples were obtained from patients with VKH disease and from healthy control subjects. Serum IL-21 level and IL-21 messenger RNA (mRNA) expression by peripheral blood mononuclear cells (PBMCs) were determined by enzyme-linked immunosorbent assay and by reverse transcriptase-polymerase chain reaction, respectively. Interleukin 17 and interferon γ levels in the supernatants of PBMCs and CD4(+) T cells cultured with anti-CD3 and anti-CD28 antibodies in the presence or absence of recombinant IL-21 were detected by enzyme-linked immunosorbent assay. RESULTS: The results showed a significantly increased serum IL-21 level, as well as higher IL-21 mRNA expression by PBMCs, in patients having chronic or recurrent active VKH disease compared with patients having inactive VKH disease and with controls. In vitro experiments showed that recombinant IL-21 significantly increased IL-17 production by PBMCs and by CD4(+) T cells from patients and from controls. However, recombinant IL-21 did not affect interferon γ expression by PBMCs or by CD4(+) T cells. CONCLUSION:Interleukin 21 may be involved in the pathogenesis of chronic or recurrent VKH disease, possibly by promoting IL-17 secretion. CLINICAL RELEVANCE: Findings from the present study suggest that IL-21 may be a potential target in the development of therapy for VKH disease.
Authors: María Carmen Cénit; Ana Márquez; Miguel Cordero-Coma; Alejandro Fonollosa; Alfredo Adán; Agustín Martínez-Berriotxoa; Victor Llorenç; David Díaz Valle; Ricardo Blanco; Joaquín Cañal; Manuel Díaz-Llopis; José Luis García Serrano; Enrique de Ramón; María José del Rio; Marina Begoña Gorroño-Echebarría; José Manuel Martín-Villa; Norberto Ortego-Centeno; Javier Martín Journal: BMC Med Genet Date: 2013-05-15 Impact factor: 2.103
Authors: Sébastien Abad; Grégoire Wieërs; Didier Colau; Claude Wildmann; Emmanuelle Delair; Robin Dhote; Antoine P Brézin; Yukata Kawakami; Pierre G Coulie; Pierre van der Bruggen Journal: Mol Vis Date: 2014-07-02 Impact factor: 2.367